Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. (Q50637600)

17 March 2018

title

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. (English)

1 reference

17 March 2018

0 references

A Miller

1

1 reference

17 March 2018

S Shapiro

2

1 reference

17 March 2018

R Gershtein

3

1 reference

17 March 2018

A Kinarty

4

1 reference

17 March 2018

H Rawashdeh

5

1 reference

17 March 2018

S Honigman

6

1 reference

17 March 2018

N Lahat

7

1 reference

17 March 2018

publication date

1 December 1998

1 reference

17 March 2018

Journal of Neuroimmunology

published in

1 reference

17 March 2018

volume

92

1 reference

17 March 2018

issue

1-2

1 reference

17 March 2018

page(s)

113-121

1 reference

17 March 2018

Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

The attraction of adhesion molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

The adhesion molecule and cytokine profile of multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

IL-10 fails to abrogate experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Macrophages regulate induction of delayed-type hypersensitivity and experimental allergic encephalomyelitis in SJL mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Late complications of immune deviation therapy in a nonhuman primate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Immunologic mechanisms and therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Tumor necrosis factor identified in multiple sclerosis brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

In vivo administration of IL-4 induces TGF-beta-producing cells and protects animals from experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

In vitro study of mediators of inflammation in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Antigen-driven bystander suppression after oral administration of antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Two types of mouse helper T-cell clone Implications for immune regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Major T-cell responses in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Copolymer 1: from basic research to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of tumor necrosis factor-alpha and nitric oxide.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Oral tolerance: immune mechanisms and treatment of autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900191-X

7 January 2021

10.1016/S0165-5728(98)00191-X

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

9916886

1 reference

17 March 2018